DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer

Information source: Hellenic Oncology Research Group
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breast Cancer

Intervention: Docetaxel (Drug); Epirubicin (Drug); Bevacizumab (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Hellenic Oncology Research Group

Official(s) and/or principal investigator(s):
Dimitris Mavrudis, MD, Principal Investigator, Affiliation: University Hospital of Crete, Dep of Medical Oncology

Summary

This study will evaluate the efficacy and toxicity of docetaxel-epirubicin combination plus bevacizumab as first line treatment in patients with metastatic and HER2 negative breast cancer.

Clinical Details

Official title: Docetaxel-epirubicin Plus Bevacizumab as First Line Therapy for Patients With Metastatic and HER2 Negative Breast Cancer. A Multicenter Phase I-II Study

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Overall Response Rate

Secondary outcome:

Toxicity assessment

Time to Tumor Progression

Overall Survival

Detailed description: A phase II trial with 142 patients demonstrated that therapy with docetaxel plus epirubicin is highly active first-line therapy for metastatic breast cancer, with acceptable toxicity profile. Recently initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab demonstrated prolonged progression-free survival, as compared with paclitaxel alone. This study will evaluate the efficacy and toxicity of docetaxel-epirubicin combination plus bevacizumab as first line treatment in patients with metastatic and HER2 negative breast cancer. Furthermore, the efficacy of the combination therapy will be correlated with the presence of circulating tumor cells (CTCs) in this population.

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- Histologically- or cytologically- confirmed metastatic breast adenocarcinoma

- No HER2 overexpression or gene amplification

- No previous therapy for metastatic breast cancer is allowed

- Age 18-75 years

- At least 12 months interval since prior adjuvant therapy with taxanes and/or

anthracyclines

- Measurable disease as defined by the presence of at least one measurable lesion

(except bone metastases, ascites or pleural effusions)

- Performance status (WHO) 0-2

- Adequate liver (serum bilirubin <1. 5 times the upper normal limit, AST and ALT <2. 5

times the upper normal limit in the absence of demonstrable liver metastases, or <5 times the UNL in the presence of liver metastases)

- Adequate renal function (serum creatinine <1. 5 times the upper normal limit

- Adequate bone marrow function (neutrophils ≥ 1. 5x 109 /L, and platelets ≥ 100x 109

/L)

- Written informed consent

Exclusion Criteria:

- Active infection

- Brain metastases

- History of significant cardiac disease (unstable angina, congestive heart failure,

myocardial infarction within the previous 6 months, ventricular arrhythmias)

- History of stroke

- Anticoagulation therapy (except of low dose aspirin <325mg)

- Other invasive malignancy except nonmelanoma skin cancer

- Psychiatric illness or social situation that would preclude study compliance

- Pregnant or lactating women

Locations and Contacts

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece

"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece

"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece

"Marika Iliadis" Hospital of Athens, Dep of Medical Oncology, Athens, Greece

401 Military Hospital of Athens, Athens, Greece

Air Forces Military Hospital of Athens, Athens, Greece

University Hospital of Crete, Dep of Medical Oncology, Heraklion, Greece

State General Hospital of Larissa, Dep of Medical Oncology, Larissa,, Greece

"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Piraeus, Greece

"Theagenion" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology, Thessaloniki, Greece

Additional Information

Starting date: May 2008
Last updated: August 18, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017